For this special webcast, Andrew broadcasts from the 50th annual meeting of the American Society of Hematology (ASH), a meeting that brings experts from all over the world to share information on the latest advances in research for blood cancers and blood related disorders. This program focuses on CML or chronic myelogenous leukemia, featuring guest expert Dr. Michael Deininger. Dr. Deininger is Associate Professor of Hematology/Medical Oncology at Oregon Health & Science University, where he specializes in cancer and blood disorders. Dr. Deininger shares late-breaking news in CML from the ASH meeting.
The discussion begins with talk of the approved medications for CML, most notably Gleevec. Dr. Deininger comments on data being released for first-line and second-line treatments for the disease. He also talks about alternative options for patients who have not had success with Gleevec, or when Gleevac stops working. Dr. Deininger addresses drug resistance, and what the options are when resistance occurs.
Regarding progress being made in finding a cure, Dr. Deininger speaks about the intricacies of what ‘cure’ really means and what this means in relation to CML. He details various factors involved in curing the disease, sharing information about recent studies and immunological control. If you or someone you know is seeking care for CML, this program can be a useful resource in your research.
Michael Deininger, M.D., Ph.D.
Chief of Hematology and Hematologic Malignancies , University of Utah, Huntsman Cancer InstituteMichael Deininger, MD, PhD, is chief of Hematology and Hematologic Malignancies for Huntsman Cancer Institute (HCI) at the University of Utah. He is a professor in the Department of Medicine at the University of Utah. Deininger's clinical interests center on leukemia, myeloproliferative neoplasms and hematopoietic stem cell transplantation. His research focuses on the biology of leukemia and development of molecularly... more >